This application is submitted in response to RFA Hl-00-012: Ancillary Studies in Lung Disease Trials. The parent trial to which this application is linked, (U01-HL62514), is testing the hypothesis that low dose inhaled nitric oxide, administered to infants 500 to 1250 g birth weight, will produce an increase in survival without chronic lung disease (CLD) from 50 percent to 61 percent at 36 week post menstrual age. The parent study is a blinded, placebo controlled, three week trial of decreasing dose nitric oxide or placebo beginning between 7 and 21 days of age. Part of the rationale supporting the parent trial is that nitric oxide may moderate pulmonary inflammation, a crucial precursor of full-blown CLD. Although the parent trial includes measurements of tracheal aspirate interleukin 1B and interleukin-8, it cannot investigate mechanisms of, nor initiation, propagation, or persistence of, pulmonary inflammation. Our proposed study will examine the role of two members of the family of transmembrane receptors, Toll-like receptors (TLRs), found on leukocytes and other cells and upregulated in response to endotoxin and to other stimuli. These substances transduce the signal propagating inflammatory mediator production. We will quantitate protein expression and mRNA expression of TLR-2, and TLR-4 from leukocytes obtained from serial tracheal aspirate samples. We will perform these serial studies in a subset of enrolled patients who will mirror the parent clinical trial sample in terms of ethnicity, gender, and severity of underlying disease.
Our specific aims are to determine if upregulation of TLR-2 and/or TLR-4 antedates development of CLD of prematurity and to determine if there is a significant correlation with severity of CLD. We will determine if the mechanism of improved outcome with NO administration occurs in association with NO-associated suppression of upregulation of TLR, a possibility for which we have supportive pilot data. Even if the parent study cannot reject the null hypothesis that nitric oxide will have no benefit in this disease, this mechanistic study will provide important new information about natural history of CLD and about crucial mechanisms of early pulmonary inflammation. Its results may also open up intriguing pathways for treatments aimed at selective diminution of pulmonary inflammation.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL070560-02
Application #
6627845
Study Section
Special Emphasis Panel (ZHL1-CSR-A (F1))
Program Officer
Berberich, Mary Anne
Project Start
2002-02-10
Project End
2006-01-31
Budget Start
2003-02-01
Budget End
2004-01-31
Support Year
2
Fiscal Year
2003
Total Cost
$298,780
Indirect Cost
Name
Children's Mercy Hosp (Kansas City, MO)
Department
Type
DUNS #
073067480
City
Kansas City
State
MO
Country
United States
Zip Code
64108
Posencheg, M A; Gow, A J; Truog, W E et al. (2010) Inhaled nitric oxide in premature infants: effect on tracheal aspirate and plasma nitric oxide metabolites. J Perinatol 30:275-80
Petrikin, Joshua E; Gaedigk, Roger; Leeder, J Steven et al. (2010) Selective Toll--like receptor expression in human fetal lung. Pediatr Res 68:335-8
Truog, William E; Xu, Dong; Ekekezie, Ikechukwu I et al. (2008) Chronic hypoxia and rat lung development: analysis by morphometry and directed microarray. Pediatr Res 64:56-62
Xu, Dong; Perez, Ricardo E; Ekekezie, Ikechukwu I et al. (2008) Epidermal growth factor-like domain 7 protects endothelial cells from hyperoxia-induced cell death. Am J Physiol Lung Cell Mol Physiol 294:L17-23
Truog, William E; Ballard, Philip L; Norberg, Michael et al. (2007) Inflammatory markers and mediators in tracheal fluid of premature infants treated with inhaled nitric oxide. Pediatrics 119:670-8
Xu, Dong; Guthrie, Jill R; Mabry, Sherry et al. (2006) Mitochondrial aldehyde dehydrogenase attenuates hyperoxia-induced cell death through activation of ERK/MAPK and PI3K-Akt pathways in lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 291:L966-75